Asked by
To ask Her Majesty’s Government what plans they have to establish
a COVID-19 specific helpline in addition to NHS 111; and whether
any such helpline could be staffed by retired medical and nursing
professionals.
The Parliamentary Under-Secretary of State, Department of Health
and Social Care ()
(Con)
My Lords, as part of its coronavirus response, NHS 111 has
already trained an additional 1,000 call-handlers. NHS England
has been clear that investment will increase as demand continues
to rise. As part of the health system’s wider response to the
coronavirus, the GMC, the NMC and other professional regulators
have written to professionals who have left their registers
within the past three years to ask them to return to support the
coronavirus response.
(CB)
My Lords, I first acknowledge the Lord Speaker’s demonstrable
leadership in deciding to work from home. We need to remember
that we are televised and we need to model the behaviour we are
asking of the rest of the country. I thank the Minister for his
response, but draw his attention to the fact that there are many
retired professional health workers who wish to contribute to the
NHS and social care needs of our population in all four countries
of the UK but who have their own health concerns. Many, like
myself, are fit enough to return to clinical practice and are of
course willing to do so. However, utilising others by quickly
teaching them a specific algorithm for the Covid-19 virus could
relieve anxiety and provide advice to our population and, in
particular, relieve NHS 111 to deal with other concerns. We are
very worried that, even in the short term, people with perhaps
severe problems who should be ringing 999, but do not know that
until they have rung 111, will have to wait a disproportionately
long time. I wonder whether we could see how quickly we could get
a specific line using the expertise of the people I referred to.
The noble Baroness, Lady Watkins, reflects the feeling of all the
House in her comments on the Lord Speaker, and I entirely endorse
her comment that we must all respect the guidance and advice
given to us by the Government. I pay tribute to the Lord Speaker
for his comments on that subject.
In terms of 111, she is entirely right that the NHS is under
acute pressure, which is particularly felt on the front line in
the interaction with concerned people who are understandably
phoning 111. The 111 system is recruiting a large number of new
handlers. In addition, we have put a letter through the GMC, NMC
and other professional bodies and there will be a registration
page on the front page of those bodies’ websites—it will be going
up very shortly, either tomorrow or very soon afterwards, I
believe—for recently retired professionals to register their
interest in rejoining their local NHS health authorities in some
way. Those applications will then be passed on to the local
authorities and triaged, and the applicants will be allocated
suitable responsibilities. I pay tribute to all those who are
thinking of returning or have returned to active service, often
putting themselves in danger and taking risks in the service of
the NHS to look after patients. The skills of the recently
retired may range from those who are younger and active and can
be on the wards through to older people who may have desk-based
tasks, but it is up to the local authorities to decide where best
they can conduct their services.
(Con)
My Lords, will my noble friend join me in congratulating the Lord
Speaker on the leadership he has given? I declare my interest, as
in the register: I work with the Dispensing Doctors’ Association.
Can my noble friend address the question of professional
indemnity for those wishing to return to practise as recently
retired nurses, doctors or other medical professionals? Can he
also address the question that I have written to him about
regarding the severe shortage on the front line of PPE, which is
apparently in warehouses? It really needs to get to the front
line.
The question of indemnity insurance is addressed in detail in the
coronavirus emergency Bill. We are fully aware of the concerns of
anyone returning to work, and indeed anyone who might have
indemnity insurance in one area of practice but who will be asked
to take on exceptional duties required as part of this
emergency—the surgeon, for instance, who takes on respiratory
support duties. Those indemnities will be thorough and will cover
all work. In terms of the warehouses for PPE, it is incredibly
important that there is load allocation according to the need for
the PPE, not necessarily the demands of local authorities. There
is therefore an active allocation of PPE to those areas that have
the highest incidence of the virus. That is being managed
centrally in a thoughtful and professional manner.
(LD)
My Lords, I direct the House to my medical and other interests in
the register. I have no doubt that NHS 111 and other helpline
medical professionals and health professionals will give the best
advice. But Professor John Ioannidis at Stanford University has
pointed out that we are making major changes in the way we run
society, on necessarily limited evidence for what happens with
this virus. Can those working on NHS 111 and any other advice
lines also take epidemiological data on the length of time and
types of symptoms and, particularly, geographical spread, and
feed that data back to research institutes inside and outside the
NHS, so that we can get the best handle possible, as soon as
possible, on how this virus operates?
The noble Lord, , is entirely right: one
of the features of this virus is its extremely unpredictable
nature. The way in which it reacts in different people at
different times is extraordinarily diverse. Some people appear to
be completely knocked out by it; some have the lightest possible
symptoms. There seems to be an alignment with age. We are all
enormously thankful that the young and very young seem to be
blessed by having the light symptoms. We are all extremely
concerned about the old, but it is not even as simple or as
linear as that. A huge investment is being put into understanding
the virus better. I am pleased to report to the Chamber that
international co-operation on that is extensive and positive, and
that British researchers are at the leading edge of pulling
together that data.
(Lab)
My Lords, this is a question on co-ordination. Yesterday, I saw
the script that 111 is using right now; it was perfectly
intelligible and sensible. However, it was out of step with what
was on Public Health England’s website. I am sure that is a
timing issue but it is rather important, because it will increase
anxiety. Moreover, the digital exclusion of the elderly and
vulnerable is a really serious problem because suggesting to
people that they should go online in the first instance is
entirely inappropriate for people who can manage a phone, but
that is about it. Many of us are probably related to people in
that position, so having plans to deal with that—as suggested by
the noble Baroness, Lady Watkins—is very important.
The noble Baroness, Lady Thornton, is right that the Government
have moved incredibly quickly, particularly in the last two
weeks. The pace of the virus has been faster than initially
expected. The response by some of our international partners has
in part conditioned our response, and we are working extremely
hard to ensure that all parts of the machine keep up with each
other. There will inevitably be occasional glitches, but I pay
tribute to the NHS, Public Health England and, in fact, the
entire Whitehall machine for moving incredibly quickly and, under
the circumstances, demonstrating a relatively high level of
consistency in the advice as policy has changed.
Asked by
To ask Her Majesty’s Government what steps they are taking to
ensure that UK production facilities are able to develop and
produce sufficient quantities of any vaccine for COVID-19.
The Parliamentary Under-Secretary of State, Department of Health
and Social Care ()
(Con)
My Lords, vaccine development is moving very rapidly but is still
at a very early stage. The Government are working closely with
industry to assess UK manufacturing capability for a range of
potential new vaccines. The type of capacity and specific route
needed to take this further will be determined by the technology
used to produce the vaccines and the types of vaccines produced.
(Lab)
I thank the Minister for that Answer. The Question is about not
just the production of vaccines but the production facilities to
mass-produce them. Understandably, the priority now must be
supporting those infected and the front-line staff with the
production of ventilators. However, we should be planning for
what comes next, as the Minister said, and the development of
vaccines is part of that. What discussions have been had, or
decisions made, between the Government and UKRI about scaling up?
When we get the vaccine, that will be fine, but what about the
ability to scale it up? We will need to build the factory now;
normally that comes after. Can we explore a little further
whether the work on scaling up is happening, as well as the
development of the vaccine?
The noble Lord, Lord McNicol, is entirely right to focus on the
importance of vaccines. The Government are extremely concerned
that the entire public have a clear line to having confidence
that they can rid themselves of the threat of the virus so that
we can all get back to work and normal life. That will not be
possible until we have a vaccine. If I may digress for a moment,
one consideration is that, for a vaccine to work, it will have to
be taken by billions; for that, it must be as safe as houses. I
contrast that with the vaccine for Ebola, where the death rate
was at nearly 80% and a just-about-good-enough approach could be
taken. However, the coronavirus has a relatively low mortality
rate and the introduction of an added risk factor into the
population is something we can avoid. For those reasons, the
development of a vaccine is considered to be at least a year or
18 months off. However, the noble Lord is entirely right that
planning for the production of the vaccine, when it is fully
developed, is front of mind for the Government.
(Con)
My Lords, ever since John Snow discovered the link between the
famous London water pump and the cholera outbreak in 1854, UK
scientists and innovators have led global efforts to tackle
infectious diseases. We should be very proud of that. However,
many UK biotechs and healthtechs which are leading the race to
fight Covid-19 are loss-leading and will struggle to raise risk
capital in the current climate to maintain operations. One very
simple intervention the Treasury could make would be to pay
R&D tax credits in advance. This would be matched very well
to each individual company and could be based simply on their
most recent claims. Will the Minister look into this as a matter
of urgency?
My noble friend has an important and exciting idea, and I am
grateful to her for communicating it to me in advance of today’s
Question. I have already taken the idea to Treasury colleagues. I
have not had a formal response, but the idea supports a pressing
and important need in the essential life sciences sector and
seems to have strong merit. I hope it will go far.
(LD)
My Lords, the Question asked by the noble Lord, Lord McNicol, was
very clear: it is not about the production of a vaccine but the
facilities to manufacture that vaccine at scale. At the moment,
the Government have made £46 million available for research into
the vaccine. What money and planning are going into the
facilities so that, once a vaccine has been made, it can be
produced at scale in the UK?
The focus on the actual production of the vaccine is a matter of
sequencing. We are moving incredibly quickly in all areas, but
the focus at the moment, I think understandably, is on trying to
get a product developed. In that respect, I bear testimony to the
Oxford Vaccine Group and Jenner Institute at Oxford University,
which have been shortlisted for the CEPI group of seven for
potential vaccine development. This is an incredibly important
development and shows the strength of Britain’s contribution to
the development of vaccines.